Literature DB >> 17313200

Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly.

Angel Lanas1, Angel Ferrandez.   

Abstract

Although use of NSAIDs and aspirin (acetylsalicylic acid) is well known to be associated with gastrointestinal (GI) complications and potential mortality, these medications continue to be widely prescribed in the elderly. Age is a significant risk factor for NSAID-induced GI events; indeed, patients >75 years of age carry the highest risk and are similar in this respect to patients with a history of peptic ulcer. Prevention of NSAID-induced gastropathy is indicated in patients at risk. It is accepted that patients >60 years of age taking NSAIDs should participate in prevention strategies such as co-therapy with proton pump inhibitors (PPIs) or misoprostol, or use of cyclo-oxygenase (COX)-2 selective NSAIDs (also called coxibs). Although up to 33% of subjects with no risk factors who receive NSAIDs over-utilise GI preventive therapies, under-utilisation of gastroprotective therapy is more prevalent among those with risk factors, of which the most frequent is age. At least half of those at risk do not receive appropriate preventive therapy, either because they do not receive co-therapy with PPIs or misoprostol or are not treated with COX-2 selective NSAIDs, or because they receive co-therapy with antacids or histamine H(2) receptor antagonists, which are not effective. Adherence to the prescribed preventive therapy is an additional problem for those who are prescribed a PPI or misoprostol. Over 30% of patients are non-adherent and the lowest rate of non-adherence is associated with the first NSAID prescription, which increases the risk of ulcer bleeding compared with those who are fully adherent. Predictors of nonadherence include long-term use of NSAIDs and a high average daily dose of NSAIDs. Predictors of adherence include a history of upper gastrointestinal events, anticoagulant use, rheumatological disease and use of low-dose salicylates, among others. Another important aspect is self-medication; this is common in the elderly, who also have several risk factors for GI complications, and may be a factor in over one-third of all NSAID-related complications. In summary, aging is a key risk factor for GI complications in patients taking NSAIDs. Appropriate prevention strategies should be used in the elderly and those at risk; special attention should be paid to compliance and self-medication.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17313200     DOI: 10.2165/00002512-200724020-00004

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  56 in total

1.  National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs.

Authors:  Neena S Abraham; Hashem B El-Serag; Michael L Johnson; Christine Hartman; Peter Richardson; Wayne A Ray; Walter Smalley
Journal:  Gastroenterology       Date:  2005-10       Impact factor: 22.682

2.  Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole.

Authors:  David Y Graham; Naurang M Agrawal; Donald R Campbell; Marian M Haber; Cyndy Collis; Nancy L Lukasik; Bidan Huang
Journal:  Arch Intern Med       Date:  2002-01-28

3.  Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.

Authors:  Jia Qing Huang; Subbaramiah Sridhar; Richard H Hunt
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

4.  Incidence and preventability of adverse drug events among older persons in the ambulatory setting.

Authors:  Jerry H Gurwitz; Terry S Field; Leslie R Harrold; Jeffrey Rothschild; Kristin Debellis; Andrew C Seger; Cynthia Cadoret; Leslie S Fish; Lawrence Garber; Michael Kelleher; David W Bates
Journal:  JAMA       Date:  2003-03-05       Impact factor: 56.272

5.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

6.  Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.

Authors:  Jay L Goldstein; Bidan Huang; Fouad Amer; Nikos G Christopoulos
Journal:  Clin Ther       Date:  2004-10       Impact factor: 3.393

7.  Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration.

Authors:  C P Armstrong; A L Blower
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

Review 8.  Review article: appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors.

Authors:  M B Kimmey; A Lanas
Journal:  Aliment Pharmacol Ther       Date:  2004-02       Impact factor: 8.171

9.  Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs.

Authors:  M C Allison; A G Howatson; C J Torrance; F D Lee; R I Russell
Journal:  N Engl J Med       Date:  1992-09-10       Impact factor: 91.245

10.  Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis.

Authors:  S E Gabriel; L Jaakkimainen; C Bombardier
Journal:  Ann Intern Med       Date:  1991-11-15       Impact factor: 25.391

View more
  21 in total

1.  High concomitant use of interacting drugs and low use of gastroprotective drugs among NSAID users in an unselected elderly population: a nationwide register-based study.

Authors:  Rickard Ljung; Yunxia Lu; Jesper Lagergren
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

2.  Prophylactic use of gastro-protective agents in patients on low-dose aspirin.

Authors:  S Balakrishnan; R Jhaj
Journal:  Br J Clin Pharmacol       Date:  2008-02-21       Impact factor: 4.335

3.  Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: a randomized, double-blind, placebo-controlled study.

Authors:  Jay C Desai; Shefali M Sanyal; Tyralee Goo; Ariel A Benson; Carol A Bodian; Kenneth M Miller; Lawrence B Cohen; James Aisenberg
Journal:  Dig Dis Sci       Date:  2008-01-26       Impact factor: 3.199

Review 4.  The clinical implications of ageing for rational drug therapy.

Authors:  Shaojun Shi; Klaus Mörike; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-01-05       Impact factor: 2.953

Review 5.  Optimal management of peptic ulcer disease in the elderly.

Authors:  Alberto Pilotto; Marilisa Franceschi; Stefania Maggi; Filomena Addante; Daniele Sancarlo
Journal:  Drugs Aging       Date:  2010-07-01       Impact factor: 3.923

6.  Molecular mechanisms elucidating why old stomach is more vulnerable to indomethacin-induced damage than young stomach.

Authors:  Hua Hong; Eun-Hee Kim; Ho Jae Lee; Yoon Jae Kim; Jong Joon Lee; Ki Baik Hahm
Journal:  Dig Dis Sci       Date:  2012-07-29       Impact factor: 3.199

Review 7.  Clinical efficacy of esomeprazole in the prevention and healing of gastrointestinal toxicity associated with NSAIDs in elderly patients.

Authors:  Corrado Blandizzi; Marco Tuccori; Rocchina Colucci; Giovanni Gori; Matteo Fornai; Luca Antonioli; Narcisa Ghisu; Mario Del Tacca
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

8.  Concomitant use of gastroprotective drugs among elderly NSAID/COX-2 selective inhibitor users: a nationwide register-based study.

Authors:  Kristina Johnell; Johan Fastbom
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

9.  Gastroprotective agent underuse in high-risk older daily nonsteroidal anti-inflammatory drug users over time.

Authors:  Zachary A Marcum; Joseph T Hanlon; Elsa S Strotmeyer; Anne B Newman; Ronald I Shorr; Eleanor M Simonsick; Douglas C Bauer; Robert Boudreau; Julie M Donohue; Subashan Perera
Journal:  J Am Geriatr Soc       Date:  2014-10-03       Impact factor: 5.562

10.  Adherence with regulatory resolutions on prevention of NSAIDS-related gastrointestinal injury in Italy.

Authors:  Sabrina Montagnani; Marco Tuccori; Arianna Testi; Michele Cristofano; Tiberio Corona; Stefano Salvadori; Carmelo Scarpignato; Corrado Blandizzi
Journal:  Int J Clin Pharm       Date:  2016-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.